IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN
| Autor: | W. Ludo van der Pol, Sanne Piepers, Elisabeth A. Cats, Nina M. van Sorge, Leonard H. van den Berg, Marc D. Jansen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Igm antibody Immunology Mismatch negativity Enzyme-Linked Immunosorbent Assay G(M1) Ganglioside Classical complement pathway Maintenance therapy hemic and lymphatic diseases medicine Immunology and Allergy Humans Complement Pathway Classical Motor Neuron Disease Complement (group theory) Analysis of Variance business.industry Immunoglobulins Intravenous Complement System Proteins Middle Aged medicine.disease In vitro Titer Neurology Immunoglobulin M Case-Control Studies Female Neurology (clinical) business Multifocal motor neuropathy |
| Zdroj: | Journal of neuroimmunology. 229(1-2) |
| ISSN: | 1872-8421 |
| Popis: | The effects of intravenous immunoglobulins (IVIg) on anti-GM1 IgM titer and function, classical complement pathway activity, and antibody-complement interaction were investigated in 62 patients with multifocal motor neuropathy (MMN). In vitro, IVIg decreased complement deposition by anti-GM1 IgM antibodies. First IVIg treatment (2 g/kg) decreased C1q and C4 concentrations and classical pathway activity in serum. In sera from patients receiving IVIg maintenance therapy (0.4 g/kg) C4 concentrations and classical pathway activity were generally lower at higher IgG concentrations. The beneficial effects of IVIg in MMN may be explained by reduced antibody-mediated complement deposition in nerves amplified by a systemically attenuated classical pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect